空间基因组学/转录组学市场：现况与预测（2024-2032）

预计预测期内（2024-2032 年），全球空间基因组学/转录组学市场规模将以 12.03% 的复合年增长率大幅增长。慢性病的流行正在推动对空间基因组学/转录组学等新的经济高效的医疗保健解决方案的需求。技术进步及其与人工智慧和生物资讯学的结合正在满足个人化医疗的需求。此外，与政府、研究机构和製药公司的伙伴关係和协作也变得越来越普遍。透过与药物研发公司合作，空间基因组学/转录组学供应商能够提供一系列专注于细胞和组织分析的产品。例如，2022 年 1 月 5 日，Bio-Techne 和 Akoya Biosciences Inc.（为研发和临床诊断界提供创新工具和生物活性试剂的全球生命科学公司）宣布合作开发第一个单细胞空间多组学工作流程，用于对组织样本进行全面、公正的分析。透过该协议，两家公司希望向市场推出自动化空间多组学工作流程，该工作流程能够以单细胞分辨率在整个玻片上对多种分析物进行快速原位分析。

根据技术类型，市场分为空间基因组学和空间转录组学。2023 年，空间基因组学市场占据了空间基因组学/转录组学市场主导地位。这主要是由于精准医疗的需求不断增长以及癌症研究的进步。客製化治疗可以清晰地瞭解组织组成、细胞相互作用和基因表现。空间基因体学有助于在细胞层面上解读癌症的复杂性。此外，这种整合将有助于组织解决空间基因组学所带来的癌症诊断和治疗日益复杂的问题，这使得研究人员能够在基因的原生空间环境中进行研究。例如，2023 年 9 月 19 日，Akoya Biosciences, Inc. 凭藉最近推出的 PhenoCycler Fusion 2.0 和 PhenoImager HT 2.0 平台升级，强有力地展示了全幻灯片空间生物学工作流程中业界领先的规模和速度。增强型 PhenoCycler-Fusion 2.0 系统使客户每週能够处理两倍的样本，使其成为市场上吞吐量最高的空间发现平台。PhenoImager 2.0 平台可直接在 HT 仪器上进行快速即时影像分析，从而将工作流程提高了 5 倍。Akoya 的客户将能够加速药物发现、临床相关生物标记的识别以及新型空间特征的开发，并具有前所未有的大规模执行全幻灯片空间生物学的能力。

根据产品类型，市场分为仪器、消耗品和其他。到 2023 年，家电领域将占据较大的市场占有率。仪器市场由大型公司主导，这些公司采用空间基因组学/转录组学解决方案，透过技术创新的快速进步来改善药物发现。此外，使用人工智慧进行空间数据分析使这些工具更加实用和有吸引力。此外，这些仪器对于理解复杂的生物系统至关重要，特别是在癌症、神经科学和发育生物学等领域。因此，空间基因组学/转录组学与人工智慧的结合正在被大公司所采用，并为製药公司开闢新的市场，使其摆脱对传统技术的依赖。

根据最终用户，市场细分为生物製药/生物技术公司、学术和研究机构、合约研究组织等。预计生物製药/生技公司在预测期内（2024-2032 年）将以显着的复合年增长率成长。研究实验室数量的快速成长、研发投入的增加以及技术的进步，为市场带来了最大的占有率。此外，药物发现和开发使公司能够识别潜在的标靶药物并开发更有效的治疗方法。这些公司正在利用空间基因组学/转录组学为客户提供更好的药物、标靶疗法和精准药物。随着公司从政府和私人公司获得充足的资金，对空间基因组学/转录组学产品的需求不断增加，继续推动市场发展。

本报告研究了全球空间基因组学/转录组学市场，并提供了有关市场动态、区域和细分分析以及公司简介的资讯。

目录

第1章市场介绍

第2章 研究方法或前提条件

第3章 执行摘要

• 业界摘要
• 分部展望
  • 市场成长的力量
• 区域展望

第4章 市场动态

• 促进因素
• 机会
• 阻碍因素
• 趋势
• PESTEL 分析
• 需求面分析
• 供给侧分析
  • 併购
  • 投资场景
  • 产业洞察：主要新创公司及其独特策略

第5章 价格分析

• 区域定价分析

第6章 全球空间基因体学/转录组学市场收入（2022-2032）

第7章 依技术类型划分的市场分析

• 空间基因体学
• 空间转录组学

第8章依产品类型划分的市场分析

• 用具
• 消耗品
• 其他

第9章 终端用户市场分析

• 生物製药/生技公司
• 学术研究所
• 开发合约组织
• 其他

第10章 区域市场分析

• 北美
  • 美国
  • 加拿大
  • 北美其他地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 其他地区

第11章价值链分析

• 边际分析
• 进入市场的企业名单

第12章竞争格局

• 比赛仪表板
• 竞争对手市场定位分析
• 波特五力分析

第13章 公司简介

• Akoya Biosciences
• Bruker Spatial Biology
• Illumina, Inc.
• Veracyte, Inc.
• Macrogen, Inc.
• Miltenyi Biotec
• Standard Biotools
• Lunaphore Technologies S.A.
• 10x Genomics
• Vizgen Inc.

第14章 缩写与先决条件

第15章 附录

Spatial Genomics & Transcriptomics deals with the spatial organization of genetic and transcriptomic information within biological systems. Spatial genomics is the study of the entire DNA collection in its natural setting. It focuses on comprehending the biological processes influenced by the physical configuration of DNA within cells and tissues. By preserving the spatial linkages of the genetic material, researchers can get to know more about gene regulation, cellular connections, and structural organization of genetic material. It is vital to get to know about gene expression, genome organization, and the effect of epigenomes while maintaining the positional context. Spatial transcriptomics is the study of the transcriptome fingerprint or net gene expression of each cell during development and within diseased tissues. It may assist in providing the necessary information on cellular phenotype, cell state, and ultimately the function of the cell and tissues.

The Spatial Genomics & Transcriptomics Market is expected to grow with a significant CAGR of 12.03% during the forecast period (2024-2032). With the increasing pervasiveness of chronic diseases, there is a demand for new cost-effective, and efficient health management solutions, such as Spatial Genomics & Transcriptomics. With advancements in technology and integration with AI and Bioinformatics, it fulfills the demand for personalized medicine. Moreover, partnerships and collaborations with governments, institutions, and pharmaceutical providers are becoming increasingly common. Through partnerships with drug discoverers, Spatial Genomics & Transcriptomics suppliers can provide various products focused on cellular and tissue analysis. For instance, on January 5, 2022, Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Akoya Biosciences Inc., announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through this agreement, the partners would bring to the market an automated, spatial multiomics workflow that can perform rapid, in situ analysis of multiple analytes, at single cell resolution, across whole slides.

Based on the technology type, the market is segmented into spatial genomics and spatial transcriptomics. The spatial genomics market dominated the spatial genomics & transcriptomics market in 2023. This is mainly due to the increased demand for precision medicine and advancements in cancer research. The tailored treatments provide explicit acumen into tissue organization, cell interactions, and gene expressions. Spatial genomics helps to decipher the complexities of cancer at the cellular level. Further, the integration assists organizations in dealing with the increasing complexities in cancer diagnosis and treatment, which is enabled by spatial genomics, as it allows researchers to study genes in their native spatial context. For instance, On Sept. 19, 2023, Akoya Biosciences, Inc. highlighted the industry-leading scale and speed in whole-slide, spatial biology workflows enabled by the recently launched PhenoCycler Fusion 2.0 and PhenoImager HT 2.0 platform upgrades. Enhancements to the PhenoCycler-Fusion 2.0 System allow customers to process twice as many samples per week, making it the highest throughput spatial discovery platform on the market. The PhenoImager 2.0 platform delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument. With an unprecedented ability to perform whole-slide spatial biology at scale, Akoya's customers can accelerate progress towards discoveries, identification of clinically relevant biomarkers, and development of novel spatial signatures.

Based on the product type, the market is segmented into instruments, consumables, and others. The instruments segment held a significant market share in 2023. The market for instruments is led by large corporations that incorporate Spatial Genomics & Transcriptomics solutions to improve drug discoveries through rapid advancements in technological innovations. Further, the use of artificial intelligence for analyzing spatial data has enhanced the utility and appeal of these instruments. Moreover, these instruments are essential for comprehending the intricate biological systems peculiarly in areas such as cancer, neuroscience, and developmental biology. Accordingly, Spatial Genomics & Transcriptomics have gained adoption among large enterprises due to integration with AI, and it opened new markets for pharmaceutical companies breaking the dependence on traditional technologies.

Based on the end users, the market has been divided into biopharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and others. Biopharmaceutical and biotechnology companies are expected to grow with a significant CAGR in the forecast period (2024-2032). With the upsurge in the number of research laboratories, rising investments in R&D, and advancements in technology, the largest share of the market. Further, drug discoveries and development enable companies to identify potential target drug targets and develop more effective therapies. These companies utilize spatial genomics & transcriptomics to offer their clients better drugs, targeted therapies, and precision medicines. The increase in demand for spatial genomics & transcriptomics products continues to fuel the market since companies are getting ample funding from the government and private organizations.

For a better understanding of the market adoption of spatial genomics & transcriptomics market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR in the forecast period (2024-2032). The increasing rampancy of chronic and infectious diseases, R&D investments, and the rise in the number of research laboratories in Asia-Pacific is fueling this market. Rapid economic growth and improvements in the healthcare infrastructure in the Asia Pacific countries are enabling the adoption of advanced genomic tools. Further, the partnership between international corporations and regional research institutes will help to boost regional revenue creation. Apart from this, the introduction of innovative and cost-effective sequencing platforms for academic and translational research is further driving the market. According to the Indian Council of Medical Research (ICMR) 2023, India had 163 Viral Research Diagnostic Laboratories, 117 Multidisciplinary Research Units (MRUs) and 35 Model Rural Health Research Units (MRHRUs). For instance, on October 27, 2022, Vizgen, announced the availability of its MERSCOPE(R) spatial genomics platform in Asia-Pacific (APAC), Europe, the Middle East, and Africa (EMEA). To support its global expansion, Vizgen has signed agreements with the distributors of the APAC region with Gene Company covering China/Hong Kong while PRIMETECH covers Japan.

Some of the major players operating in the market include Akoya Biosciences, Bruker Spatial Biology, Illumina, Inc., Veracyte, Inc., Macrogen, Inc., Miltenyi Biotec, Standard Biotools, Lunaphore Technologies S.A., 10x Genomics, Vizgen Inc.

TABLE OF CONTENTS

1.Market Introduction

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.Research Methodology or Assumption

• 2.1. Research Process of the Spatial Genomics & Transcriptomics Market
• 2.2. Research Methodology of the Spatial Genomics & Transcriptomics Market
• 2.3. Respondent Profile

3.Executive Summary

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.Market Dynamics

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Start-ups and Their Unique Strategies

5.Pricing Analysis

• 5.1. Regional Pricing Analysis
• 5.2. Regional Pricing Analysis

6.Global Spatial Genomics & Transcriptomics Market Revenue (USD Bn), 2022-2032F

7.Market Insights By Technology Type

• 7.1. Spatial Genomics
• 7.2. Spatial Transcriptomics

8.Market Insights By Product Type

• 8.1. Instruments
• 8.2. Consumables
• 8.3. Others

9.Market Insights By End-Users

• 9.1. Biopharmaceutical and Biotechnology Companies
• 9.2. Academic and Research Institutes
• 9.3. Contract Research Organization
• 9.4. Others

10.Market Insights By Region

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. France
  • 10.2.3. Uk
  • 10.2.4. Spain
  • 10.2.5. Italy
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of APAC
• 10.4. Rest of The World

11.Value Chain Analysis

• 11.1. Marginal Analysis
• 11.2. List of Market Participants

12.Competitive Landscape

• 12.1. Competition Dashboard
• 12.2. Competitor Market Positioning Analysis
• 12.3. Porter Five Forces Analysis

13.Company Profiles

• 13.1. Akoya Biosciences
  • 13.1.1. Company Overview
  • 13.1.2. Key Financials
  • 13.1.3. Swot Analysis
  • 13.1.4. Product Portfolio
  • 13.1.5. Recent Developments
• 13.2. Bruker Spatial Biology
• 13.3. Illumina, Inc.
• 13.4. Veracyte, Inc.
• 13.5. Macrogen, Inc.
• 13.6. Miltenyi Biotec
• 13.7. Standard Biotools
• 13.8. Lunaphore Technologies S.A.
• 13.9. 10x Genomics
• 13.10. Vizgen Inc.

14.Acronyms & Assumption

15.Annexure